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AbsTrACT
background Inherited CDKN2A mutation is a strong 
risk factor for cutaneous melanoma. Moreover, carriers 
have been found to have poor melanoma-specific 
survival. In this study, responses to novel immunotherapy 
agents in CDKN2A mutation carriers with metastatic 
melanoma were evaluated.
Methods  CDKN2A mutation carriers that have 
developed metastatic melanoma and undergone 
immunotherapy treatments were identified among 
carriers enrolled in follow-up studies for familial 
melanoma. the carriers’ responses were compared with 
responses reported in phase III clinical trials for CtLA-4 
and pD-1 inhibitors. From publicly available data sets, 
melanomas with somatic CDKN2A mutation were 
analysed for association with tumour mutational load.
results eleven of 19 carriers (58%) responded to the 
therapy, a significantly higher frequency than observed in 
clinical trials (p=0.03, binomial test against an expected 
rate of 37%). Further, 6 of the 19 carriers (32%) had 
complete response, a significantly higher frequency 
than observed in clinical trials (p=0.01, binomial test 
against an expected rate of 7%). In 118 melanomas with 
somatic CDKN2A mutations, significantly higher total 
numbers of mutations were observed compared with 
761 melanomas without CDKN2A mutation (Wilcoxon 
test, p<0.001).
Conclusion patients with CDKN2A mutated melanoma 
may have improved immunotherapy responses due to 
increased tumour mutational load, resulting in more 
neoantigens and stronger antitumorous immune 
responses.
bACkground
Inherited pathogenic variants in the CDKN2A 
gene are among the strongest known risk factors 
for cutaneous melanoma.1 CDKN2A is a tumour 
suppressor gene on chromosome 9p21 encoding for 
the cell cycle inhibitors p16 and p14ARF. Germline 
CDKN2A mutations are identified in familial mela-
noma probands but are rare in the normal popu-
lation (<0.1%).2 Mutation carriers have a risk of 
melanoma that is >65-fold increased and a lifetime 
penetrance for melanoma of >70%.1 CDKN2A 
mutation carriers have a high risk of developing 
multiple primary melanomas and also other 
cancers.1 3 4 Additionally, a previous study reported 
that germline CDKN2A mutation carriers had 
inferior melanoma-specific survival that was inde-
pendent of American Joint Committee on Cancer 
(AJCC) stage, age and sex, and not associated with 
the diagnosis of subsequent primary melanomas or 
other cancers.5 Somatic CDKN2A mutations and 
deletions are frequent driver events in melanoma 
tumours and CDKN2A deletions and loss of p16 
protein have been associated with increased tumour 
proliferation, increased risk of metastases and 
decreased patient survival.6–10 Melanomas are, in 
general, tumours with very high mutation burden, 
with frequent ultraviolet light-induced mutations in 
many genes.11 Besides CDKN2A, BRAF and NRAS 
are the genes that are most frequently mutated in 
melanoma tumours.6 7
Disseminated melanoma is notoriously difficult to 
treat with standard chemotherapy agents and there 
are still no single or combination chemotherapy 
regimens that have shown to prolong the patient’s 
survival. In recent years, however, effective targeted 
therapies and immunotherapy regimens, particu-
larly the CTLA-4 and PD-1 blocking antibodies 
have emerged for the treatment of melanoma.12–15 
These, so called immune checkpoint inhibitors, act 
by blocking an innate negative regulation of T cell 
activation and response, thus allowing the immune 
system to attack the tumour. The emergence of 
these treatments has revolutionised the melanoma 
oncology field, but unfortunately a considerable 
fraction of patients with melanoma do not respond 
to immunotherapies. Immune checkpoint inhibitors 
are also associated with immune-related side effects 
that can be serious and life-threatening.12–15 For 
this reason, it is important to increase the knowl-
edge about predictive factors and the efficacy of 
the therapies in different patient groups. Clinical 
factors such as poor performance status, multiple 
sites of metastases and high tumour burden predict 
inferior responses, as well as when immunothera-
pies are given after progression on preceding lines 
of therapies. Yet, the knowledge on other predictive 
factors for checkpoint inhibitors is limited. Patients 
with tumours that harbour activating BRAF muta-
tions respond equally to immune checkpoint inhibi-
tors as those without such mutations.13–15 However, 
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there is growing evidence that tumour mutational burden is a 
strong independent predictive factor for efficacy of immuno-
therapies.7 16–18 So far, there have been no studies addressing the 
effect of immunotherapy regimens in patients with melanoma 
with germline CDKN2A mutations.
MeThods
Patient accrual
CDKN2A mutation carriers that have developed metastatic 
melanoma and undergone immunotherapy treatments were 
identified by reviewing medical records of carriers enrolled in 
follow-up studies for familial melanoma. The different studies 
in which mutation carriers were identified have previously 
been described.1–4 19 Data were collected on the type of germ-
line CDKN2A mutation and its effect on p16 and p14ARF, 
age and sex of the patient, tumour stage (according to the 
eighth edition of the AJCC cancer staging system, imple-
mented January 2018), BRAF mutation status of tumours, 
type of immunotherapy, line of treatment, previous therapies, 
responses, survival and treatment side effects. The carriers 
received the immune checkpoint inhibitors according to stan-
dard dosage and treatment schedules; CTLA.4 blockade: 
ipilimumab, 3 mg/kg, four courses, every third week or tremeli-
mumab, 15 mg/kg, four courses every 90th day; PD1-blockade: 
nivolumab, 3 mg/kg every second week or pembrolizumab, 
2 mg/kg, every third week, both drugs as long as tolerated or 
until progression; CTLA-4/PD-1 blockade: ipilimumab 3 mg/
kg+nivolumab 1 mg/kg, four courses every third week followed 
by nivolumab 3 mg/kg every second week as long as tolerated 
or until progression; PD-1/BRAF/MEK-blockade: according to 
study protocol ( clinicaltrials. gov/ ct2/ show/ NCT02967692). 
Adoptive T cell transfer was performed according to the study 
by Verdegaal et al.20
response data
The best response achieved was assessed in the CDKN2A muta-
tion carriers and compared with responses reported in the 
phase III clinical trials in patients with metastatic melanoma for 
ipilimumab, pembrolizumab, nivolumab and the ipilimumab/
nivolumab combination.12–15 By a binomial test it was evaluated 
if there was a statistically significant difference in the response 
rate in the carriers compared with an expected rate. The 
expected rate was calculated as a median of the responses in the 
clinical trials weighted against the numbers of carriers receiving 
each type of therapy (the T cell transfer and PD-1/BRAF/MEK 
therapies were assumed to have responses as high as for the ipili-
mumab/nivolumab combination).
Mutational load analyses
From publicly available data sets, as described in the study by 
Cirenajwis et al,21 melanomas with somatic CDKN2A mutation 
were analysed for association with tumour mutational load. 
In the tumours, total numbers of mutations found in 1461 
frequently mutated cancer-associated genes were analysed. 
Non-parametrical Wilcoxon test was used to calculate the p value 
for difference in the total number of mutations with or without 
CDKN2A mutation. The p value was adjusted for study from 
which the tumours originated and for origin of tumours from 
primary melanomas or metastatic lesions. For linear regression, 
mutational load was log-transformed to approximate a normal 
distribution.
resulTs
Patients and immunotherapy response
Among the 19 identified patients, nine different pathogenic 
germline mutations were found, most affecting both p16 and 
p14ARF (table 1). There were 10 men and 9 women and the 
median age when treatment started was 55 years (range 29–75 
years). Fifteen of the 19 patients (79%) had M1c-d disease which 
is a higher frequency compared with the patients that have been 
enrolled in the ipilimumab, pembrolizumab, nivolumab and 
ipilimumab/nivolumab trials (71%, 64%, 61% and 58%, respec-
tively). Five of the patients (26%) had brain metastasis (M1d 
according to the eighth AJCC staging system), such patients 
belong to a particularly poor prognosis group, and are usually 
not well represented in clinical trials (12%, 10%, 4% and 4% 
in the ipilimumab, pembrolizumab, nivolumab and ipilimumab/
nivolumab trials, respectively). Twelve of the patients (63%) had 
received previous lines of treatments (the majority BRAF ±MEK 
inhibitors) compared with 100%, 35%, 0% and 0% in the ipili-
mumab, pembrolizumab, nivolumab and ipilimumab/nivolumab 
trials, respectively. Activating mutations in the BRAF gene were 
detected in the melanoma tumours of 14 patients (74%).
Eight patients received CTLA-4 blockade, eight patients 
received PD-1 blockade, three patients received dual CTLA-4 and 
PD-1 blockade, one patient had adoptive T cell transfer therapy 
and one patient received triple combination of PD-1, BRAF and 
MEK inhibitors. Eleven of the 19 carriers (58%) responded to 
immunotherapy compared with 10%, 33%, 43% and 57% of 
the patients in the ipilimumab, pembrolizumab, nivolumab and 
ipilimumab/nivolumab trials, respectively12–15 (p=0.03, bino-
mial test against an expected rate of 37%). Further, 6 of the 19 
carriers (32%) had complete response, which is superior to what 
has been observed in any of the clinical trials where complete 
response was observed in 2%, 6%, 8% and 12% in the ipili-
mumab, pembrolizumab, nivolumab and ipilimumab/nivolumab 
trials, respectively (p=0.01, binomial test against an expected 
rate of 7%). Treatment-related grade 3–4 side effects were 
observed in the carriers at frequencies comparable to what has 
been reported in clinical trials. The overall and progression-free 
survival in months for each of the patients is shown in table 1. 
Of the eight patients that received CTLA-4 inhibitors, six (75%) 
were alive 1 year after the start of the treatment and five (63%) 
were alive 2 years after treatment start. To compare, the 1-year 
and 2-year overall survival in the phase III ipilimumab study 
was 46% and 24%, respectively.12 Among the carriers receiving 
PD-1 inhibitors or the CTLA-4/PD-1 inhibitor combination, a 
significant fraction of the patients had ongoing survival that was 
less than a year, and hence the 1-year and 2-year survival rates 
cannot be calculated for these therapies yet.
Mutation burden of melanoma tumours
Since total mutational and neoantigen load in tumours has been 
found to be a major predictive factor for the response to immu-
notherapies7 16 17 we sought to investigate mutation burden in 
CDKN2A mutated tumours. For this purpose, we combined 
mutation data from 879 melanoma tumours from four publicly 
available studies.21 Majority of tumours were from metastatic 
lesions (82%), while only 17% were from primary tumours. Of 
the 879 tumours, 118 were found to have deleterious CDKN2A 
mutations (figure 1A). Interestingly, the tumours with CDKN2A 
mutations had significantly higher total numbers of mutations 
in their genome compared with the tumours without CDKN2A 
mutation. (Wilcoxon test, P<0.001, figure 1B). Further, the 
association between mutational load and CDKN2A mutation 
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status was confirmed in a linear regression model adjusted 
for study from which the tumours originated and for origin 
of tumours from primary melanomas or metastatic lesions, 
P<0.001. No significant differences were found in the mutation 
load depending on if tumours had mutations in BRAF or NRAS 
(data not shown).
ConClusIons
From this collaborative effort between oncogenic clinics in 
Sweden, Italy, The Netherlands, Spain and Australia we report 
of 19 CDKN2A mutation carriers with metastatic melanoma 
that have received novel immunotherapy treatments. Although 
a substantially higher frequency of the patients with CDKN2A 
mutated melanoma had M1c-M1d disease and/or were previ-
ously treated, they had responses to the immunotherapy regi-
mens that were superior to what has been reported in clinical 
trials.12–15 This was an unexpected finding and the underlying 
mechanisms for the responsiveness to immunotherapy among 
the carriers are uncertain. However, we explored a possible aeti-
ology by analysing the mutation burden of somatic CDKN2A 
mutated tumours. Interestingly an increased number of genomic 
mutations was observed in melanomas with somatic CDKN2A 
mutation. Since cell cycle checkpoint controls are tightly asso-
ciated with DNA damage response and repair mechanisms it is 
possible that CDKN2A mutated cells accumulate an increased 
number of mutations. Patients with CDKN2A mutated melanoma 
may therefore have improved immunotherapy responses due to 
increased tumour mutational load, resulting in more neoantigens 
and stronger antitumorous immune responses. However, such 
an association would optimally be explored by relating the muta-
tion burden of tumours from CDKN2A mutation carriers to 
immunotherapy responses, however, the low number of carriers 
is a limiting factor for such analyses. Further studies are needed 
on the association between CDKN2A mutations, mutation load 
and immunotherapy responses and on underlying mechanisms 
for such associations.
The relatively low number of the carriers needs to be perceived 
in the light of the low population frequency of the CDKN2A 
mutation and while the majority of carriers develop melanoma, 
most known carriers are under surveillance to endorse preven-
tion and early detection, with the result that relatively few have 
developed metastatic melanoma in our familial melanoma clinics 
in the past few years, during which the checkpoint inhibitors 
have been available.
PD-1 inhibitors have recently been found very effective, 
also in the adjuvant situation, that is, to prevent recurrence in 
patients operated for high-risk cutaneous melanomas. This is 
reassuring for CDKN2A mutation carriers that often develop 
multiple primary melanomas during their life spans. Further, 
the CTLA-4 and PD-1 inhibitors were first approved for treat-
ment of disseminated melanoma, but later PD-1 blockade has 
also been approved for the treatment of other cancers including 
oropharyngeal and lung cancers although the response rates 
are inferior to what has been observed in melanoma. CDKN2A 
mutation carriers have significantly increased risks for lung and 
oropharyngeal cancers1 3 but we have yet not identified any 
Figure 1 CDKN2A mutations and mutational load in melanoma tumours. (A) Distribution of somatic mutations in the CDKN2A gene created by the 
MutationMapper tool at cBioportal. highlighted are the three most frequently recurring mutations (p114L/t, r80* and W110*) observed in the melanoma 
tumours. (B) Mutational load analysis in 879 melanoma tumours, 118 tumours with CDKN2A mutations (mut) and 761 tumours without CDKN2A mutations 
(wt). the y axis shows total numbers of mutations found per tumour sample in 1461 frequently mutated cancer-associated genes. the non-parametrical 
Wilcoxon test was used to calculate the p value. the association between mutational load and CDKN2A mutation status was confirmed in a linear regression 
model adjusted for study from which the tumours originated and for origin of tumours from primary melanomas or metastatic lesions, p<0.001. For linear 
regression, mutational load was log-transformed to approximate a normal distribution.
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CDKN2A mutation carrier that has received PD-1 blockade 
for such cancers. Considering the responses among the 
patients with melanoma it is possible that carriers affected by 
lung and oropharyngeal cancers would respond well to such 
immunotherapies.
In familial melanoma clinics, CDKN2A mutation carriers are 
frequently encountered and here knowledge on risk factors, 
outcomes and treatments is invaluable. The CDKN2A mutation 
carriers in the study had a good response rate to the novel immu-
notherapy regimens, which we believe is helpful information for 
caregivers that manage CDKN2A mutation carriers and their 
families. Based on our findings, CDKN2A mutation predicts a 
good response to immunotherapies, possibly due to increased 
mutational load in CDKN2A mutated tumours. Further, in the 
light of the previous publication on poor melanoma-specific 
survival in the CDKN2A mutation carriers (carried out in the 
‘pre-checkpoint inhibitor era’),1 these findings are reassuring for 
this group of patients.
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